Rene Oda

About Rene Oda

This author has not yet filled in any details.
So far Rene Oda has created 251 blog entries.

Interleukin Genetics Files Form 15

WALTHAM, Mass, – August 14, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced it has filed a Form 15 with the Securities and Exchange Commission completing the process of delisting and deregistering its securities under the Exchange Act.

The Company announced on July 25, 2017, that it would begin the process of delisting and deregistering its securities and filed a Form 25 on August 4, 2017 as part of the process.

About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and […]

Interleukin Genetics Files Form 25

WALTHAM, Mass, – August 4, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced it has filed a Form 25 with the Securities and Exchange Commission in furtherance of its plan to delist and deregister its securities in order to obtain relief from its reporting obligations under the Exchange Act and preserve capital for shareholders and the satisfaction of debtors.

The Company announced on July 25, 2017, that it would begin the process of delisting and deregistering its securities.  The Company intends to file a Form 15 with the Securities and Exchange Commission on or about August 14, 2017 in order to complete the delisting and deregistration process commonly referred to as “going dark.”

About Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: […]

Interleukin Genetics to Wind-Up and Pursue a Plan of Liquidation

Will begin process of delisting and deregistering

WALTHAM, Mass, – July 24, 2017Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the adoption of a plan to wind-up and liquidate the Company subject to shareholder approval via a Proxy Statement with a special meeting of the Shareholders to be held sometime in early August.  In an effort to preserve capital for shareholders and the satisfaction of debtors, the Company will begin the process of delisting under Section 12(b) of the Securities Act and deregister its issued stock under Section 15(d) of the Securities Act.

“While this decision was extremely difficult, the Company has fully pursued and vetted all other options,” said Mark Carbeau, Chief Executive Officer.  “We believe this path […]

Interleukin Genetics To Explore Strategic Alternatives, Reduce Workforce

WALTHAM, Mass. – July 3, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced that it will pursue strategic alternatives for the Company and will reduce the Company’s workforce by five employees (63%) as part of a plan to reduce operating costs.

“While this decision was extremely difficult, it is important to preserve capital as we assess our options,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “I and the other Board members are personally grateful to our departing employees and the exceptional team members throughout the history of the Company who have advanced the contributions that Interleukin Genetics has made to precision medicine and to the advancement of inflammation science broadly.”

The Company was unable to secure a clinical […]

Interleukin Genetics Reports First Quarter 2017 Financial Results

Focus on Advances in Cardiovascular Testing Platform

WALTHAM, Mass. – May 12, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial results for its first quarter of 2017, ended March 31, 2017, and provided a corporate update.

“We continued to advance our refined strategy that focuses on the potential utility of our Interleukin-1 (IL-1) genetic platform in the development of new classes of drugs for cardiac disease, and management of patients who have suffered previous cardiac events,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics. “We believe our proprietary genetic patterns have potential to accelerate clinical development through more targeted patient recruitment and may help address important questions such as dose responses, side-effect profiles and pricing/reimbursement strategies. Commercially, […]

Interleukin Genetics Reports Fourth Quarter and Year-End 2016 Financial Results

Announces Refined Business Strategy Focused on Advances in Cardiovascular Test Technology

WALTHAM, MA – April 18, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, today announced financial and operational results for its fiscal fourth quarter and full fiscal year ending December 31, 2016.

“2016 was a pivotal year for Interleukin Genetics, as we generated compelling new data regarding the potential utility of our Interleukin-1 (IL-1) genetic platform in the development of new classes of drugs for cardiac disease, and management of patients who have suffered previous cardiac events,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics. “We believe our proprietary genetic patterns have potential to accelerate clinical development […]

Interleukin-1 Genotypes Are Predictive of Cardiovascular Events in Patients With Elevated Lipoprotein(a)

Second Study Validates Role in Recurrent Cardiac Events

WALTHAM, MA – March 20, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today the presentation of clinical data from “The Ioannina Study” at the 66th Annual Scientific Session & Expo of the American College of Cardiology (ACC 2017) in Washington, DC that demonstrates the ability of certain interleukin-1 (IL-1) genetic patterns together with elevated lipoprotein (a) (Lp(a)) to predict recurrent atherosclerotic cardiac events. Dr. Bechlioulis and co-workers reported the new findings from the University Hospital of Ioannina (Greece) along with collaborators from the University of California at San Diego.

In the longitudinal study (median time 43 months) of 1,084 patients who […]

Interleukin Genetics Signs Second Employer Agreement in Pittsburgh Region

Spang & Company to Offer ILUSTRA™ to Employees Through Pittsburgh Business Group on Health Collaboration

WALTHAM, MA – March 13, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has signed an agreement with Spang & Company, a diversified manufacturing company, to offer the ILUSTRA Inflammation Management Program to their employees and their families as an enhancement to the company’s employee benefits plan.

Spang & Company is an employer-member of the Pittsburgh Business Group on Health (PBGH), the region’s leading employer-led coalition and as a member received early access to the ILUSTRA Program. Under the terms of the agreement, ILUSTRA will be made available to all of Spang & […]

Interleukin Genetics Establishes Partnership with Greater Philadelphia Business Coalition on Health

Expands Availability of the ILUSTRATM Inflammation Management Program with Deployment of First Employer in Philadelphia Region

WALTHAM, MA – March 2, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a partnership with the Greater Philadelphia Business Coalition on Health (GPBCH) to make the ILUSTRA Inflammation Management Program available to GPBCH employer-members in the Philadelphia area as part of a company’s enhanced employee benefits plan.

The collaboration is designed to introduce ILUSTRA to coalition members and to assist employer members in implementing and evaluating the innovative ILUSTRA program.

“We’re proud to be working with GPBCH to educate its members on the health benefits that may result […]

Interleukin Genetics Deploys ILUSTRATM Inflammation Management Program with mPulse Mobile Employees

Enhanced Benefit Can Deliver Significant Health and Economic Value by Targeting Chronic Inflammation

WALTHAM, MA – February 23, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a relationship with mPulse Mobile, a leader in mobile health engagement, to offer the ILUSTRA Inflammation Management Program to their employees as an enhancement to the company’s employee benefits plan.

“This innovative program is a clear match with our company values and mission,” said Brian Chudleigh, Chief Financial Officer at mPulse Mobile. “Affecting behavioral change toward a healthy lifestyle is the key to realizing long-term health, wellness and reduced healthcare costs. I am impressed with the ILUSTRA program […]